Jin Medical International
ZJYL
3 hedge funds and large institutions have $210K invested in Jin Medical International in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0.25% less ownership
Funds ownership: 0.37% → 0.12% (-0.25%)
36% less capital invested
Capital invested by funds: $326K → $210K (-$116K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$110K |
| 2 |
JP Morgan Chase
New York
|
+$3.48K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$548 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$318K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8.51K |
ZJYL Hedge Fund Activity: Q3 2023 in Review
3 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in Jin Medical International (ZJYL) for Q3 2023, worth a combined $210K — down 36% from $326K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ZJYL positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $110K. The largest seller was Nomura Holdings, exiting entirely with an estimated $318K sold.
- 3 institutional investors held Jin Medical International (ZJYL) as of Q3 2023, up from 2 in Q2 2023.
- Funds reported $210K of Jin Medical International stock for Q3 2023, down 36% quarter-over-quarter.
- 3 funds opened new Jin Medical International positions in Q3 2023 and 2 closed out, a net change of +1 holder.
- The largest Jin Medical International buyer in Q3 2023 was Virtu Financial, an estimated $110K added.
- The largest Jin Medical International seller in Q3 2023 was Nomura Holdings, an estimated $318K sold.
Based on aggregated 13F filings for Q3 2023.